9 weighted blankets that can reduce anxiety and help you sleep better
You can use these blankets to relieve anxiety. The extra weight is believed to help calm the nervous system, mimicking the feeling of being hugged and promoting a sense of security and relaxation. These blankets can also help with sleep problems like insomnia because they reduce anxiety and promote relaxation. Weighted blankets can help individuals fall asleep faster, stay asleep longer, and experience better overall sleep quality.
Choosing the correct weight for your blanket depends on your size. The Sleep Foundation recommends that adults choose a weighted blanket between 5% and 12% of their body weight for the best results. A proper blanket should allow for comfort and movement regardless of weight.
Original price: $329
Bearaby's king-sized weighted blanket covers the entire bed so that you can share the calming effects of this beautiful weighted blanket. Bearaby blankets are weighted by their patented yarn. This yarn is layered upon itself to achieve the desired weight. This design also allows for a hand-knitted look and feel, with breathable fabric that encourages air circulation. You can also buy this blanket on Amazon.
Original price: $230
Silk & Snow's Hand-Knitted Weighted Blanket is woven with natural cotton for easier care. It's hand-knitted with soft cotton yarns in an open-knit structure, which promotes airflow and prevents overheating. The weight is achieved through the layers of woven cotton and does not use glass or plastic pellets.
This Luxome weighted blanket with a removable cover has a cotton interior shell filled with glass beads. The outer cover is made of Minky – a plush, microfiber fabric that feels soft and velvety – and lyocell from bamboo. The inner blanket is often made of 100% cotton percale weave.
The Baloo blanket made by Baloo Living is designed to provide a deep pressure touch to melt away stress and anxiety and promote relaxation and better sleep. These blankets are made of eco-friendly and sustainable materials, including 100% cotton, lead-free glass beads, and plastic-free packaging.
Original price: $219
Nolah Sleep's chunky knit weighted blanket's breathable open knit is soft and cozy so you can achieve your best sleep. The blanket features 100% polyester jersey-knitted fabric stuffed with breathable 100% polyester filling. This blanket has a tighter weave compared to some of the other knitted blankets on the market, so it looks chunkier. It only comes in cream.
Original price: $169
Brooklinen's weighted blanket is made of textured cotton and weighted with a layer of tiny glass beads. It is a high-quality cotton blend that offers a soft, breathable, and comfortable feel. It gets high marks for its even weight distribution.
Original price: $179
Casper's weighted blanket is filled with small glass microbeads that are evenly distributed for a comfortable and soothing feeling customers like. This blanket features a 100% cotton cover that is breathable and smooth, which helps regulate temperature. This blanket has three weight options (10, 15, and 20 pounds).
Original price: $168
This weighted blanket features a two-toned cover design: one side is a bamboo-based pewter gray, and the other is a dark gray. It is weighted with glass beads to alleviate stress and anxiety, and premium rayon fabric made from bamboo helps keep you feeling cool.
For more Deals, visit www.foxnews.com/deals.
Original price: $149
The Tempur-Pedic Weighted Blanket is filled with glass beads evenly distributed across the entire body to calm you. It has a plush, washable cover and is available in a modest charcoal grey color and two weights.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
30 minutes ago
- Medscape
Ovarian Cancer Risk Rises Soon After IBS Diagnosis
TOPLINE: Women with a new diagnosis of irritable bowel syndrome (IBS) have a significantly higher risk for ovarian cancer at 3 months and 6 months post-diagnosis, but this risk is no longer elevated beyond 8 months. METHODOLOGY: Ovarian cancer often presents with nonspecific symptoms overlapping those of IBS. The frequency of misdiagnosis remains unknown, and not all IBS guidelines recommend screening for ovarian cancer. Researchers conducted a retrospective cohort study using US administrative claims data to compare ovarian cancer incidence in adult women with and without a new IBS diagnosis. Diagnostic codes were used to identify cases of IBS and ovarian cancer. TAKEAWAY: The cohort comprised 9804 women with IBS and 79,804 women without IBS, identified between January 2017 and December 2020. Women with IBS had a significantly higher risk for ovarian cancer at 3 months (hazard ratio [HR], 1.71; P = .02) and 6 months (HR, 1.43; P = .02), but not beyond 8 months post-diagnosis. Women with both IBS and endometriosis had an even greater risk for ovarian cancer at 3 months (HR, 4.20; P = .01), 6 months (HR, 3.52; P = .01), and after 1 year (HR, 2.67; P = .04). Increasing age was significantly associated with higher ovarian cancer incidence only in women younger than 50 years (HR, 1.07; P < .01), regardless of IBS status. IN PRACTICE: 'Identifying patient-specific risk factors, such as chronic pelvic pain or endometriosis, could help develop tailored risk profiles and improve the approach to personalized care in women with IBS-type symptoms,' the authors wrote. SOURCE: This study was led by Andrea Shin, Vatche and Tamar Manoukian Division of Digestive Diseases, University of California, Los Angeles. It was published online in Alimentary Pharmacology & Therapeutics. LIMITATIONS: The use of diagnostic codes for identifying IBS may have led to misclassification or reflected symptoms rather than confirmed and validated diagnosis. DISCLOSURES: This study received support from the National Institutes of Health. Some authors reported serving as consultants, advisors, and/or receiving research support from pharmaceutical and healthcare companies; one author reported having stock options. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
30 minutes ago
- Medscape
Benzene in Acne Products: What to Know Now
When an independent laboratory filed a citizen's petition in March 2024, urging the FDA to recall and suspend the sale of acne products containing benzoyl peroxide after finding what it termed unacceptably high levels of benzene in acne products it tested, it ignited a range of reactions in the medical community and consumers. Responses ranged from fear to indifference, with even some dermatologists passing off the request as nonsense. However, concerns about the potential for benzoyl peroxide-containing acne products to break down into benzene, a known human carcinogen, have been ongoing. In recent months, as research has accumulated, so has a clearer picture of the risk. The FDA has taken action, although some contend the agency has not done enough, and experts involved are better focused — and sometimes in closer agreement — on how to move forward to increase safety for the products, considered one of the most effective topical acne treatments and the only effective remedy for many patients. Medscape Medical News reached out to John S. Barbieri, MD, MBA, assistant professor of dermatology at Harvard Medical School and director of the Advanced Acne Therapeutics Clinic at Brigham and Women's Hospital, both in Boston, and David Light, president and co-founder of Valisure, the independent laboratory in New Haven, Connecticut, that filed the petition, asking for an update of what they've found out in recent months (they both have published research recently), what they believe needs to be done moving forward, and their advice on how clinicians should be talking to their patients about the products. 'Right now, to me, it's a nonissue clinically,' said Barbieri, who has researched and written about the issue extensively. 'I don't worry about this in my day-to-day practice.' However, he's adamant that more needs to be done to maximize the safety of the products, that patients need to be educated about precautions they can take, and that manufacturers need to focus on getting the benzene levels in their products to what he and others say is achievable — zero. Product Heterogeneity Researchers have found a wide range of levels of benzene in products. That's good news, so to speak, in regard to fixing the problem. As Barbieri and Christopher Bunick, MD, PhD, associate professor of dermatology at Yale University School of Medicine, New Haven, Connecticut, wrote in a recent Viewpoint in JAMA Dermatology, 'there has been considerable heterogeneity observed between brands and product lines, suggesting opportunities to improve formulation, production, and distribution practices to maximize the safety of benzoyl peroxide-containing products.' The range of benzene found, for instance, in the Valisure analysis leading to the citizen's petition was sometimes over 800 times the FDA's conditional limit of 2 parts per million. The JAMA paper also cites a study, published in May 2025, by Bunick, Light, and others, finding that cold storage may reduce benzene formation, and a study co-authored by Barbieri, which found that leave-on benzoyl peroxide products contained lower concentrations of benzene, possibly because they are often manufactured in smaller batches than washes 'and thus may cool more quickly,' they wrote. Recent Recalls In March 2025, the FDA alerted the public and industry to the results of its testing of 95 acne products with benzoyl peroxide for possible benzene contamination, following the receipt of the Valisure test results. As a result of the FDA alert, six companies voluntarily recalled some of their products, and another company voluntarily recalled its product after its own testing. FDA Input? Under nonbinding FDA guidance issued in December 2023, benzene levels in products using carbomers (thickeners) should not exceed 2 parts per million. Medscape Medical News reached out to the FDA, asking if the agency had any other information pertaining to developments in the manufacturing of benzoyl peroxide acne products. A spokesperson referred only to the March 2025 information about recalls and its finding that more than 90% of the benzoyl peroxide acne products it tested had undetectable or very low levels of benzene. Manufacturers' Mission Manufacturers need to do more, Light and Barbieri agreed, to monitor benzene levels and reduce them. 'I'm quite supportive of the paper they wrote,' Light told Medscape Medical News , referring to the JAMA update co-authored by Barbieri and Bunick. 'I appreciate their push on the manufacturers' side,' a stance Light has taken from the start. Information on exactly what the product manufacturers are doing, even after the March recalls and the FDA testing, is scarce, Light and Barbieri agreed. (Light's analyses have previously been the target of some criticism, contending he is mostly interested in winning lawsuits against companies and boosting profits. He has filed patents related to, among other areas, the prevention of the formation of impurities, including benzene, in drug products such as benzoyl peroxide-containing products. In response, Light said his goals have always been focused on public health and consumer protection. 'Our analyses have not only been rigorously reviewed through the peer-review process in multiple journals,' he said, 'but each of our five FDA Citizen Petitions on benzene contamination in major consumer product categories has been followed by testing and validation by regulators and companies that confirmed unacceptably high levels of benzene and initiated recalls.') The Consumer Health Products Association, a trade group that many of the benzoyl peroxide product manufacturers belong to, posted the following statement on its site after the citizen's petition was filed last year: 'Benzene is not intentionally added to any consumer product, and it is important that proper quality control measures are in place to both detect impurities and reduce potential contamination during the manufacturing process.' But it offered no more specific information about individual manufacturers' procedures or attempts at improvements. Beyond quality control measures, manufacturers must pay attention to shipping and distribution, which can affect benzene levels as temperatures rise, Barbieri said. 'Consumer confidence is really important here,' he added. Manufacturers should also transparently share their benzene data, Barbieri and Light agreed. Besides acne products, according to the FDA, hand sanitizers, aerosol antiperspirants, and sunscreen sprays have been recalled because of benzene concerns. Empowering Patients Meanwhile, clinicians can advise patients to take a number of steps to minimize the risk for benzene exposure, according to Barbieri and Light. Discarding expired products or those that have been exposed to high temperatures — such as being left in a hot car — is one recommendation. Replacing products every 10-12 weeks is also probably wise, Barbieri said, but he concedes that more data is needed about the stability of the products at room temperature. Whether refrigerating the products is better than keeping them at room temperature hasn't been fully researched, he noted. Lowering the temperature does help with benzene formation, Light said. In his studies, he found that a single acne product incubated at 158 °C, similar to a hot car, released benzene at concentrations about 1270 times higher than the US Environmental Protection Agency threshold for cancer risk via long-term inhalation. He also cautions against storing the products in the bathroom medicine cabinet because of the higher temperatures. In addition, consumers shouldn't rely on 'best products' lists based on analyses of benzene levels, Barbieri told Medscape Medical News , because the same product could have been purchased in different ways — such as picking it up from the store directly or ordering it online and then having it sit on a hot doorstep for hours. Be cautious using online retailers and pharmacies, he said, for those reasons — the products could have had potentially higher temperature exposure during shipping. Ultraviolet exposure is similar to heat in its effects, Light pointed out. Barbieri said those who use leave-on products should consider sun protection, which, he added, is a useful general recommendation for acne management in general. Looking Forward: Getting to Zero While progress has been made, and awareness of the risks has increased, there's work to be done, experts agreed. 'It's still an important and relevant issue,' Barbieri said. 'We want to be doing as much as we can to mitigate the risk as much as possible. Even if the risk is 0.00001, if we can make it zero, we should make it zero.' Barbieri and Bunick have reported no relevant disclosures. Light has filed patents related to the prevention of the formation of impurities, including benzene, in drug products, such as benzoyl peroxide products. The Journal of Investigative Dermatology study published in May 2025 was funded by Valisure.
Forbes
31 minutes ago
- Forbes
Is Ambient AI A Commodity In Healthcare?
CHINA - 2025/02/11: In this photo illustration, a doximity logo is displayed on the screen of a ... More smartphone. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Ambient AI is one of the most prominent trends in healthcare technology, particularly among frontline healthcare providers. Tools that can listen in the background and auto-generate clinical notes are reshaping how physicians, NPs, and PAs manage documentation. Until recently, most of these solutions came with steep price tags or complex integrations. Now, Doximity has entered the game with Doximity Scribe, its own AI-powered ambient listening tool—and it's offering it completely free to verified U.S. clinicians. Of course, nothing in this world is truly free. However, in this case, there are no subscriptions, no hidden fees, and no audio data retention—just a strategic move by Doximity to establish itself as the go-to digital platform for clinicians. How It Works Users can access Doximity Scribe on both desktop and mobile. Open the Doximity app and look under the "AI Tools" tab, or go to on your browser. Start Scribe at the beginning of a patient visit. With one tap, it begins to listen securely like a second set of clinically trained ears. As the clinician speaks with the patient, the Scribe captures the clinical conversation in real-time. It filters out small talk and focuses on medically relevant information, such as new symptoms, changes in medication, and key historical points. When the clinician uses Doximity Dialer, Doximity's HIPAA-compliant telehealth tool that allows clinicians to call or video chat with patients from their devices while hiding their number, Scribe integrates directly into the workflow (currently in beta). This setup allows the clinician to conduct the visit and document it on the same screen, eliminating the need to switch between apps or devices. After the encounter, stop or pause the Scribe. It will instantly generate a draft clinical note based on what it heard. Reviewing the note is crucial. Scribe offers a solid first draft, but clinicians must ensure accuracy and completeness. Ultimately, the clinician is the final editor before copying it into their EMR. Final Thoughts Doximity Scribe doesn't replace clinical judgment, but it is free, and it will be interesting to see whether this "free" product will increase adoption. The biggest hurdle is simple: Scribe doesn't integrate with the EMR. Clinicians have to copy and paste notes, which is a challenge. How will the clinician transfer the final note, which is text data from their personal phone or laptop, to a hospital laptop or desktop? It is not an open network where files can be easily air-dropped or connected within the enterprise. The lack of EMR integration remains the most significant hurdle, which is precisely why large health systems tend to opt for fully integrated solutions. Still, smaller healthcare organizations could see real value in using Scribe to save costs without sacrificing quality. The bigger question now is who's next. As Doximity sets the bar by offering a free ambient AI tool, it's only a matter of time before other vendors follow suit.
